These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 32996763)

  • 1. Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides.
    Stoessel A; Groysbeck N; Guyot L; Barret L; Nominé Y; Nguekeu-Zebaze L; Bender A; Voilquin L; Lutz T; Pallaoro N; Blocat M; Deville C; Masson M; Zuber G; Chatton B; Donzeau M
    Bioconjug Chem; 2020 Oct; 31(10):2421-2430. PubMed ID: 32996763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells.
    Lee S; Park S; Nguyen MT; Lee E; Kim J; Baek S; Kim CJ; Jang YJ; Choe H
    BMB Rep; 2019 Aug; 52(8):496-501. PubMed ID: 30670149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of Potent Anti-HER1/2 Immunotoxins by Protein Ligation Using Split Inteins.
    Pirzer T; Becher KS; Rieker M; Meckel T; Mootz HD; Kolmar H
    ACS Chem Biol; 2018 Aug; 13(8):2058-2066. PubMed ID: 29920062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.
    Zielinski R; Lyakhov I; Jacobs A; Chertov O; Kramer-Marek G; Francella N; Stephen A; Fisher R; Blumenthal R; Capala J
    J Immunother; 2009 Oct; 32(8):817-25. PubMed ID: 19752752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble Cytoplasmic Expression and Purification of Immunotoxin HER2(scFv)-PE24B as a Maltose Binding Protein Fusion.
    Park S; Nguyen MQ; Ta HKK; Nguyen MT; Lee G; Kim CJ; Jang YJ; Choe H
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain.
    Liu H; Seijsing J; Frejd FY; Tolmachev V; Gräslund T
    Int J Oncol; 2015 Aug; 47(2):601-9. PubMed ID: 26046132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with
    Nguyen MQ; Kim DH; Shim HJ; Ta HKK; Vu TL; Nguyen TKO; Lim JC; Choe H
    Mol Cells; 2023 Dec; 46(12):764-777. PubMed ID: 38052492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of a modular immunotoxin connected by polyionic adapter peptides.
    Kleinschmidt M; Rudolph R; Lilie H
    J Mol Biol; 2003 Mar; 327(2):445-52. PubMed ID: 12628249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.
    Weldon JE; Pastan I
    FEBS J; 2011 Dec; 278(23):4683-700. PubMed ID: 21585657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.
    Weldon JE; Skarzynski M; Therres JA; Ostovitz JR; Zhou H; Kreitman RJ; Pastan I
    Bioconjug Chem; 2015 Jun; 26(6):1120-8. PubMed ID: 25997032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of VGRNb-PE immunotoxin in transplastomic lettuce (Lactuca sativa L.).
    Mirzaee M; Jalali-Javaran M; Moieni A; Zeinali S; Behdani M
    Plant Mol Biol; 2018 May; 97(1-2):103-112. PubMed ID: 29633168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency.
    Sokolova EA; Zdobnova TA; Stremovskiy OA; Balalaeva IV; Deyev SM
    Biochemistry (Mosc); 2014 Dec; 79(12):1376-81. PubMed ID: 25716732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention.
    Fleming BD; Urban DJ; Hall MD; Longerich T; Greten TF; Pastan I; Ho M
    Hepatology; 2020 May; 71(5):1696-1711. PubMed ID: 31520528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Studies of the expression, purification, renaturation and biologic activity of an anti-CEA immunotoxin].
    Yang H; He D; Chao K; Lin Q; You S; Huang HL
    Sheng Wu Gong Cheng Xue Bao; 2004 May; 20(3):348-51. PubMed ID: 15971603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic and apoptotic properties of a novel nano-toxin formulation based on biologically synthesized silver nanoparticle loaded with recombinant truncated pseudomonas exotoxin A.
    Gholami N; Cohan RA; Razavi A; Bigdeli R; Dashbolaghi A; Asgary V
    J Cell Physiol; 2020 Apr; 235(4):3711-3720. PubMed ID: 31578716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Creation and anti-cancer potency in HeLa cells of a novel chimeric toxin, HMGNCIDIN, composed of HMGN2 a-helical domain and PE38 KDEL domain III.
    Xiong WB; Huang N; Feng Y; Wu Q; Wang BY
    Chin Med J (Engl); 2008 Jan; 121(1):82-5. PubMed ID: 18208672
    [No Abstract]   [Full Text] [Related]  

  • 17. Preparation of Diphtheria and Pseudomonas Exotoxin A Immunotoxins and Evaluation of Their Cytotoxicity Effect on SK-BR-3, BT-474, and MDA-MB-231 Breast Cancer Cell Lines.
    Amoozadeh S; Hemmati M; Farajollahi MM; Akbari N; Tarighi P
    Cancer Invest; 2019; 37(10):546-557. PubMed ID: 31597492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Construction, expression, and activity of a novel immunotoxin comprising a humanized antiepidermal growth factor receptor scFv and modified Pseudomonas aeruginosa exotoxin A.
    Akbari B; Farajnia S; Zarghami N; Mahdieh N; Rahmati M; Khosroshahi SA; Barzegar A; Rahbarnia L
    Anticancer Drugs; 2017 Mar; 28(3):263-270. PubMed ID: 27861173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
    Chen H; Gao J; Lu Y; Kou G; Zhang H; Fan L; Sun Z; Guo Y; Zhong Y
    J Control Release; 2008 Jun; 128(3):209-16. PubMed ID: 18450313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity.
    Martin-Killias P; Stefan N; Rothschild S; Plückthun A; Zangemeister-Wittke U
    Clin Cancer Res; 2011 Jan; 17(1):100-10. PubMed ID: 21075824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.